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Abstract
Several studies demonstrated that treatment with mesenchymal stem cells (MSCs) reduces cisplatin mortality in mice.
Microvesicles (MVs) released from MSCs were previously shown to favor renal repair in non lethal toxic and ischemic acute
renal injury (AKI). In the present study we investigated the effects of MSC-derived MVs in SCID mice survival in lethal
cisplatin-induced AKI. Moreover, we evaluated in vitro the effect of MVs on cisplatin-induced apoptosis of human renal
tubular epithelial cells and the molecular mechanisms involved. Two different regimens of MV injection were used. The
single administration of MVs ameliorated renal function and morphology, and improved survival but did not prevent
chronic tubular injury and persistent increase in BUN and creatinine. Multiple injections of MVs further decreased mortality
and at day 21 surviving mice showed normal histology and renal function. The mechanism of protection was mainly
ascribed to an anti-apoptotic effect of MVs. In vitro studies demonstrated that MVs up-regulated in cisplatin-treated human
tubular epithelial cells anti-apoptotic genes, such as Bcl-xL, Bcl2 and BIRC8 and down-regulated genes that have a central
role in the execution-phase of cell apoptosis such as Casp1, Casp8 and LTA. In conclusion, MVs released from MSCs were
found to exert a pro-survival effect on renal cells in vitro and in vivo, suggesting that MVs may contribute to renal protection
conferred by MSCs.
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Introduction
Several studies demonstrated that the administration of in vitro
expanded bone marrow mesenchymal stem cells (MSCs) improves
acute kidney injury (AKI) [1]; in particular the infusion of MSCs
was shown to favor functional and morphological recovery in
rodent models of AKI induced by cisplatin [2–4], glycerol [5] and
ischemia-reperfusion injury [6,7]. However, the mechanisms
involved in renal regeneration induced by MSCs remain
controversial. Despite the reports that MSCs may localize within
the regenerating tubules [2,5], only a transient accumulation of
MSCs in the renal vasculature seems to be required for renal
repair [7]. MSCs favor tubular regeneration, which is mainly
sustained by the division of tubular cells survived to injury [8] by a
paracrine mechanism. Moreover, the study of Bi et al. [4] showed
that the factors produced by the cells may replace the therapeutic
effect of MSCs.
Besides soluble factors, we demonstrated that microvesicles
(MVs) derived from adult human MSCs contribute to kidney
repair in glycerol- [9] and ischemia-reperfusion [10] -induced
AKI. MVs are small vesicles released by cells that carry membrane
and cytoplasmic constituents of the cells from which they originate
[11–14]. Ratajczak et al., demonstrated that embryonic stem cell
derived MVs may reprogram hematopoietic progenitors by
horizontal transfer of mRNA and protein delivery [15]. Subse-
quent studies showed that beside embryonic, also adult stem cell-
derived MVs shuttle selected patterns of mRNA and miRNA,
suggesting a role of MVs in the genetic exchange between cells
[15–18]. Quesemberry et al. [19] proposed that MVs play a
critical role in the continuum model of stem cell biology.
We recently characterized the surface receptors and the
mRNA/miRNA content of MVs derived from human MSCs
[9,18]. MSC-derived MVs were shown to express several adhesion
molecules some of which, namely CD44 and CD29, were found to
be instrumental in MV internalization in renal tubular cells [9].
The mRNAs and miRNAs content of MVs derived from MSCs
associated with the mesenchymal differentiative phenotype and
with several cell functions involved in the control of transcription,
proliferation and cell immune regulation [9,18]. We also
demonstrated the MV-mediated transfer of functional mRNAs
and miRNAs to tubular epithelial cells [9,18,20].
In this work, we focused on the effects of MSC-derived MVs on
survival in a lethal model of AKI induced by cisplatin in SCID
mice. Moreover, we evaluated in vitro the effect of MVs on
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33115cisplatin-induced apoptosis of renal tubular epithelial cells and the
molecular mechanisms involved.
Results
MVs derived from MSCs reduced mortality induced by
cisplatin
SCID mice are known to be very sensitive to cisplatin treatment
[3]. In our experimental setting, SCID mice invariably died within
5 days. Survival curves of SCID mice with AKI given vehicle alone
or MVs are shown in figure 1 and table 1. Two regimens of MV
administration were used. The single injection (siMVs) of 100 mg
MVs 8 hours after cisplatin administration significantly increased
survival to 60% at day 14 and 40% at day 21, in respect to mice
treated with vehicle alone or with a single dose of RNase-
inactivated MVs. Multiple injections of MVs (miMVs) (Figure 1)
further increased survival to 80% at day 21.
MSC-derived MVs improved renal function and
morphology in cisplatin-induced AKI
Blood urea nitrogen (BUN) and creatinine levels peaked at day
4 and stabilized to high values until death in mice treated with
cisplatin and vehicle alone or with a single dose of RNase-
inactivated MVs. As shown in table 1, the siMVs improved renal
function at day 4 but in AKI mice surviving at days 14 and 21,
BUN and creatinine levels remained more elevated than in
cisplatin-untreated controls. In mice receiving miMVs, BUN and
creatinine levels significantly decreased in parallel with improved
survival, to reach levels not statistically different from those of
cisplatin-untreated controls (Table 1).
At day 4 after cisplatin injection, kidneys of mice treated with
vehicle alone or with a single injection of RNase-inactivated MVs
showed severe tubular lesions (Figure 2 and Table 1), consisting in
loss of brush border, flattening and loss of the tubular epithelium,
nuclear fragmentation, luminal cell debris and hyaline casts. No
histological glomerular changes were detectable.
Treatment with a siMVs attenuated tubular injury on days 4
(Figure 2 and Table 1). In particular, protein tubular casts were
absent and the extent of necrosis was reduced in respect to mice
given vehicle alone. At day 14, a further improvement in tubular
injury was observed in survived mice treated with a siMVs.
However, a chronic tubular injury persisted up to day 21. At this
time several tubules were atrophic. No protein casts were observed
at this time.
Treatment with miMVs was significantly more effective than
siMVs. At day 21, the renal structure appeared normal (Figure 2
and Table 1).
Table 1. Body weight, survival, renal function and morphology in SCID mice injected with cisplatin and different regimens of MVs.
DAY 4 DAY 14 DAY 21
Control CIS CIS+siMV
CIS+
RNase-MV CIS+miMV CIS CIS+siMV
CIS+
RNase-MV CIS+miMV CIS CIS+siMV
CIS+
RNase-MV CIS+miMV
Body weght (g) 24.361.6 16.861.4 1961.8 17.661.4 18.961.3 - 15.562.1 - 20.860.17
{ - 14,761,9 - 23,163,3
{
BUN (mg/dl) 2464 123612.6 75610.9
* 10969.7 3862.15
*,
{ -7 1 69.4 - 2666
{ -6 9 623 - 23.3 61.2
{
Crea (mg/dl) 0.260.01 0.860.2 0.5660.15* 0.860.35 0.460.05
*,
{ - 0.4260.15 - 0.3660.07
{ - 0.4060.16 - 0.2860.03
{
% of survival 100 100 100 100 100 0 60 0 80 0 40 0 80
Casts (n/HPF) 0 3.761.56 0.2660.13
* 2.961.65 0.160.04
*,
{ -0 . 3 60.3 - 0
{ - 0.5560.23 - 0
{
Tubular
Necrosis (n/HPF)
0 3.761.03 1.860.32
* 3.460.9 0
*,
{ - 0.7560.25 - 0
{ - 2.2560.25 - 0
{
Results are expressed as mean6SD; ANOVA with Dunnet’s multicomparison test:
* p,0.05 siMV and miMV treatments vs cisplatin (CIS);
{ p,0.05 miMV vs siMV.
CIS=cisplatin injection; CIS+siMV=cisplatin treated with single injection of MVs; CIS+RNase-MV=cisplatin treated with injection of MV pre-treated with RNase;
CIS+miMV=cisplatin treated with multiple injection of MVs.
doi:10.1371/journal.pone.0033115.t001
Figure 1. Schematic representation of the protocol of cisplatin
induced AKI and MV administration regimens and survival
curves. A) Graph showing time-points of cisplatin administration,
siMVs or miMVs and the time-points of sacrifice. B) Survival curves of
SCID mice with cisplatin induced AKI treated with different regiments of
MVs administration. All mice receiving vehicle alone died within 5 days.
Mice that received siMVs or miMVs injections survived significantly
longer than control mice treated with vehicle alone or with a si(RNase-
inactivated)MVs. Data was analysed via a log-rank test: * p,0.05 siMV vs
CIS; ** p,0.05 miMV vs siMV. Abbreviations: vehicle=cisplatin treated
mice injected with vehicle alone; siMV=cisplatin treated mice with
single injection of MVs; miMV=cisplatin treated mice with multiple
injection of MVs; RNase MV=cisplatin treated mice injected with a
single dose of MVs pre-treated with RNase.
doi:10.1371/journal.pone.0033115.g001
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shuttled by MVs could be translated in proteins in murine tubular
cells after cisplatin induced AKI, we used as reporters SUMO-1
and POLR2E, which mRNAs are present in MVs derived from
human MSCs and that are transferred from MVs to renal cells [9].
Using anti human POLR2E and SUMO-1 antibodies, de novo
expression of human proteins with a nuclear and cytoplasmatic
localization could be detected in tubules of mice with cisplatin-
AKI treated with MVs but not in those untreated, indicating that
specific mRNA shuttled by MVs can be translated into proteins in
vivo (Figure 3).
Since renal tubular apoptosis was suggested as a mechanism of
cisplatin induced AKI [21,22], we investigated whether MVs exert
an anti-apoptotic activity on tubular cells of AKI mice. At day 4
after cisplatin administration, numerous Tunel-positive cells were
detected in renal section of cisplatin-mice given vehicle alone
(Figure 4). Administration of a siMVs, significantly reduced renal
apoptotic cells at day 4, but they remained elevated at day 14 and
21 (Figure 4). In contrast, in mice treated with miMVs, a sustained
significant decrease of apoptosis was observed and at day 21
apoptosis was almost absent.
TheeffectofMV-treatmentontubularcellregenerationinSCID
micewithAKIwasexploredbyevaluatingPCNAexpressionandby
BrdU uptake. In mice treated with the single dose, a significant
increase in tubular cell proliferation was observed as an attempt to
counteract the tubular cell loss due to apoptosis (Figure 4). In mice
treatedwithmultipledose,whereapoptosiswasminimalorabsent,no
significant increase in tubular cell proliferation was observed
(Figure 4).
Effect of MVs on apoptosis and apoptotic gene
expression by cultured human tubular epithelial cells
treated with cisplatin
reatmentofhumantubularepithelialcells(TECs)withcisplatinin
vitro induced apoptosis which was significantly inhibited by different
doses of MSC-derived MVs (Figure 5). Instead, MVs derived from
human fibroblasts did not significantly inhibit TEC apoptosis
(Figure 5A).
Toinvestigatethemechanisminvolvedintheanti-apoptoticeffect
ofMVswecomparedthegeneexpressionprofileofuntreatedTECs
withTECstreatedwithcisplatin,inthepresenceorabsenceofMVs.
After 24 hours of stimulation with cisplatin the activation of
programmedcelldeathpathwaysinTECswasobserved,asdetected
by the activation of genes involved in growth arrest conditions, such
asGADD45A,andinapoptosissuchasBcl-10,CASP-1,CASP-8,LTA,
TP73 and CASP-10. Moreover, the down-regulation of anti-
apoptotic genes such as Bcl2, Bcl-XL, Akt1 and TRAF2 was present
(not shown). Comparing the cisplatin-treated TECs exposed or not
toMVs,up-regulationofsomegenesinvolvedintheinhibitionofthe
apoptosis and the down-regulation of genes involved in the
execution-phase of apoptosis could be observed (Table 2).
Figure 2. MV infusion protects SCID mice with cisplatin-induced AKI from tubular injury. Representative micrographs of renal histology of
healthy SCID mice and of SCID mice treated with cisplatin and injected with vehicle alone or with MV pre-treated with RNase or with different
regiments of MVs (single or multiple injections) and sacrificed at different time points (day 4, 14 and 21). Original Magnification: 6200. The typical
aspect of intra-tubular casts, tubular necrosis and tubular atrophy are respectively shown by asterisks, arrows and head arrows.
doi:10.1371/journal.pone.0033115.g002
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such as Bcl-xL, Bcl2 and BIRC8 and the down-regulation of genes
that have a central role in the execution-phase of cell apoptosis
(Casp1, Casp8 and LTA) in TECs treated with cisplatin plus MVs in
respect to TECs treated with cisplatin alone (Figure 5B and C).
To obtain in vitro evidence of de novo human protein expression
in murine TECs by MV-mediated horizontal transfer of mRNA,
we used as reporter genes POLR2E and SUMO-1. Human
POLR2E mRNA was detected by RT-PCR after 1 hour of MV
incubation with TECs (Figure 3). The primers used did not
recognize murine mRNA as seen by negative RT-PCR in RNA
extracted from control murine TECs, treated with cisplatin. De
novo cytoplasmic and nuclear expression of human POLR2E and
SUMO-1 proteins were detected in murine TECs after 24 hours
incubation with cisplatin and MVs (Figure 3).
Discussion
Several studies demonstrated that the administration of MSCs
reverses AKI in different experimental models [2–7]. These
beneficial effects were shown to be associated with the re-entry
into cycle of renal tubular cells survived to injury [8]. The
mechanisms have been mainly ascribed to a paracrine support of
MSC to kidney repair. Consistently, Bi et al. [4] demonstrated that
the administration of conditioned medium from MSCs may mimic
the beneficial effects of the MSC administration, indicating that
the tubular engraftment of the MSCs is not necessary. We recently
reported that intravenously administration of MVs derived from
human MSCs, has the same efficacy of MSCs on the functional
and morphological recovery of glycerol-induced AKI in SCID
mice [9].
Little is known at present on the biogenesis and the molecular
composition of MVs produced by stem cells in different environ-
mental conditions. It is suppose that the production of MVs is
enhanced after appropriate stimulation. In the present study the
serum starvation of MSCs was used as stimulus to enhance MV
production and the effect of MVs was evaluated in a lethal model of
AKI induced by cisplatin administration. Previous studies demon-
strated that the administration of MSCs (intravenously or
intraperitoneally) improves the survival in cisplatin induced AKI
[2,3]byaparacrinemechanism[4,23].WefoundthatMSC-derived
MVssignificantlyimprovedsurvivalincisplatintreatedSCIDmice.
Two different regimens of MVs injection were used. The single
administration of MVs ameliorated renal function and morphology
and improved survival. However, at day 21 cisplatin treated mice
given siMVs, showed chronic tubular injury and persistent increase
inBUNandcreatinine.WhenMVswereadministeredwithmultiple
injections, the mortality further decreased and at day 21 survived
mice showed normal histology and renal function. The mechanism
of protection as judged by the significant decrease of Tunel positive
cells in all survived mice was mainly ascribed to an anti-apoptotic
effect of MVs. In vitro studies further supported this mechanism.
Indeed, it has been shown that cisplatin induces death of TECs by a
mechanism of apoptosis [24]. We found that incubation of cultured
human TECs with MVs derived from MSCs significantly inhibited
invitroapoptosisinducedbycisplatin.Thiseffectwasassociatedwith
the down-regulation of caspase-1 in tubular cells. Caspase-1 has
been described as the main mediator of in vitro and in vivo cisplatin-
[25] as well as ischemic-induced AKI [26]. Moreover, caspase-1
deficient mice are functionally and histologically protected against
cisplatin-induced AKI [25]. For this reason, caspase-1 may be an
important target for the development of inhibitors which might
prevent cisplatin-induced AKI. In this study, we show that MVs
could prevent in vitro cisplatin-induced tubular apoptosis by down-
regulating caspase-1 mRNA. These data suggests that MVs could
mediate, at least in part, the protective effect of MSCs in this model
of renal injury.
As previously reported a species-specificity of MVs was not
observed as MVs derived from human MSCs were incorporated
Figure 3. De novo in vitro and in vivo expression of human proteins after cisplatin and MVs treatment. A) Representative confocal
micrographs showing the nuclear and cytoplasmatic expression of human POLR2E and SUMO-1 proteins in vivo, in kidney sections of cisplatin-AKI
(AKI-CIS) mice treated or not with MVs and sacrificed 48 hours later, and in vitro by TECs treated with cisplatin and cultured in the absence (vehicle) or
in the presence of 50 mg of MVs (MV) for 24 hours. Nuclei were counterstained with Hoechst dye. Original magnification: 6400 for kidney sections
and 6630 for TECs. B) 1610
5 TECs treated with cisplatin and cultured in the absence (CIS) or in the presence of two different preparations of MVs
(+MV) for 1 hour were analysed by RT-PCR for specific human mRNA POLR2E. Bands of PCR products specific for human POLR2E of the expected size
(90 pb) were detected in a 4% agarose gel electrophoresis. As positive control the extract of human bone marrow-derived MSCs (BM-MSC) was used.
The * indicates the control without cDNA.
doi:10.1371/journal.pone.0033115.g003
Stem Cell-Derived Microvesicles in Cisplatin AKI
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33115Figure 4. Renal cell apoptosis and proliferation in cisplatin-AKI mice untreated or treated with different regiments of MVs. A)
Quantification of Tunel-positive cells/high power field (hpf) at different time points. Data are expressed as mean 6SD of 8 different mice for each
experimental condition. ANOVA with Dunnet’s multicomparison test was performed: * p,0.05 siMVs or miMVs vs CIS; ** p,0.05 miMVs vs siMVs.
Representative micrographs of Tunel staining of renal sections of cisplatin mice given vehicle alone (day 4) and of cisplatin mice treated with different
regiments of MVs at different time points (4, 14 and 21 days). Original magnification:6400. B) Quantification of PCNA positive cells/hpf and of BrdU
positive cells/hpf at different time points. BrdU was injected intraperitoneally for 2 successive days before mice being killed. Data are expressed as
mean 6SD of 8 different mice for each experimental condition. ANOVA with Dunnet’s multicomparison test was performed: * p,0.05 siMVs versus
CIS. Abbreviations: Ctrl=healthy mice; CIS=cisplatin treated mice injected with vehicle alone; MV=cisplatin treated mice with single injection of
MVs.
doi:10.1371/journal.pone.0033115.g004
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vivo [9,15,20].
RNA inactivation in MVs reduced the in vivo effect on survival
and functional and morphological recovery induced by MVs,
suggesting a mechanism dependent on RNA delivery. Although
MVs protect RNAs from physiological concentrations of RNase,
the pre-treatment of MVs with high concentration of RNase can
inactivate the RNAs [9,10,16,20]. Bioanalyzer RNA profile of
RNase-treated MVs showed a reduction of 18S and 28S ribosomal
RNA residues and the quantitative RT-PCR showed significant
reduction of the ACT B, POLR2E and SUMO-1 mRNA content
taken as reporter mRNA.
In vitro evidence for an effective horizontal transfer of mRNA
was obtained by the presence of the human specific mRNA for
POLR2E and by the de novo human protein expression of human
POLR2E and SUMO-1 in MV-treated cisplatin TECs. This was
confirmed in vivo where human POLR2 and SUMO-1 proteins
were expressed by tubular cells of mice with cisplatin induced-AKI
treated with MVs. We previously demonstrated that selected
miRNAs enriched within human MVs are transferred to renal
tubular epithelial cells of mice and are functional on their specific
targets [18].
In conclusion, MVs released from bone marrow-derived MSCs
were found to exert a pro-survival effect on renal cells in vitro and in
vivo, suggesting that MVs may contribute to protection from AKI
conferred by MSCs. Further studies are needed to investigate
whether MVs may find a potential clinical application in human
AKI.
Materials and Methods
Isolation and characterization of bone marrow MSCs
MSCs were obtained from Lonza (Basel, Switzerland), cultured
and characterized as previously described [9,10]. Briefly, the
MSCs were cultured in the presence of Mesenchymal Stem Cells
Basal Medium (MSCBM, Lonza). To expand the MSCs, the
adherent monolayer was detached by trypsin treatment for
5 minutes at 37uC, after 15 days for the first passage and every
7 days for subsequent passages. Cells were seeded at a density of
10,000 cells/cm
2 and used within the passage six. At each passage,
cells were counted and analyzed for immunophenotype by
cytofluorimetric analysis. The following antibodies, all phycoery-
thrin (PE) or fluorescein isothiocyanate (FITC) conjugated were
used: anti-CD105, -CD146, -CD90 (Miltenyi Biotech, Bergisch
Gladbach, Germany); -CD29, -CD44, -CD73, -CD34, -CD45, -
CD80, -CD86, -CD166, HLA-I (Becton Dickinson Biosciences
Pharmingen, San Jose, CA). Mouse IgG isotypic controls were
from Dakocytomation (Copenhagen, Denmark).
All the cell preparations at different passages of culture
expressed the typical MSC markers: CD105, CD73, CD44,
CD90, CD166 and CD146. They also expressed HLA class I.
MSC preparations did not express hematopoietic markers like
CD45, CD14 and CD34. They also did not express the co-
stimulatory molecules (CD80, CD86 and CD40).
The adipogenic, osteogenic and chondrogenic differentiation
ability of MSCs was determined as previously described [9].
Human fibroblasts from dermas, used us control, were obtained
from Lonza and maintained in DMEM (Sigma, St. Lousi, MO)
with 10% FCS (Euroclone, Wetherby, UK) [9].
Isolation and characterization of MVs
MVs were obtained from supernatants of MSCs and of fibroblasts,
cultured overnight in RPMI deprived of Fetal Calf Serum (FCS) and
supplemented with 0.5% of BSA (Sigma). The viability of cells
Figure 5. In vitro anti-apoptotic effects of MVs on TECs. A) The
percentage of apoptotic TECs after incubation with 5 mg/ml of cisplatin
was evaluated by the Tunel assay. TECs were incubated in the presence
of cisplatin with or without different doses of MVs derived from BM-
MSCs or fibroblasts (10 or 30 mg/ml) and 3% FCS (Ctrl=TECs incubated
48 hours in the presence of 3% FCS only). Results are expressed as
mean6SD of 4 different experiments. Analyses of variance with
Newmann-Keuls multicomparison test was performed: *p,0.05 MVs
(30 mg) vs vehicle alone. B) Histograms showing the relative expression
(Rq) of different anti-apoptotic genes in cisplatin (TEC CIS) and cisplatin-
MV treated tubular cells (TEC CIS+MV) in respect to control cells treated
with vehicle alone (TEC). Experiments are performed in triplicate. Data
was analysed via a Student’s t test (unpaired, 2-tailed); * p,0.05 TEC CIS
vs TEC; ** p,0.05 TEC CIS+MV vs TEC CIS; *** p,0.05 TEC CIS+MV vs
TEC. C) Histograms showing the relative expression (Rq) of pro-
apoptotic genes in cisplatin (TEC CIS) and cisplatin-MV treated tubular
cells (TEC CIS+MV) in respect to control cells (TEC). Experiments are
performed in triplicate. Data was analysed via a Student’s t test
(unpaired, 2-tailed); * p,0.05 TEC CIS vs TEC; ** p,0.05 TEC CIS+MV vs
TEC CIS.
doi:10.1371/journal.pone.0033115.g005
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8564.3% for fibroblast as detected by trypan blue exclusion [9].
No apoptotic cells were detected by Tunel assay in MSCs and
2.861.3% apoptotic cell were detected for fibroblast. To obtain
MVs, after centrifugation at 10,000 g for 20 minutes to remove
debris,cell-freesupernatantswerecentrifugedat100,000 g(Beckman
Coulter Optima L-90K ultracentrifuge) for one hour at 4uC, washed
in serum-free medium 199 containing N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonicacid(HEPES)25mM(Sigma)andsubmittedtoa
second ultracentrifugation in the same conditions. The protein
content of MVs was quantified by Bradford method (BioRad,
Hercules,CA, USA). Endotoxin contamination of MVswas excluded
by Limulus test according to the manufacturer’s instruction (Charles
River Laboratories, Inc., Wilmington, MA, USA) and MVs were
stored at -80uC. FACS analyses on isolated MVs were done as
described [9,10]. Briefly, by cytofluorimetric analyses MVs were
detected mainly below the forward scatter signal corresponding to 1-
mm beads. By Zetasizer Nano (Malvern Instruments, Malvern
Worcestershire, United Kingdom), that is an instrument that permit
to discriminate micro-particles inferior to 1 mm of diameter, the size
o fM V sr a n g e df r o m8 0n mt o1mm, with a mean value of 135 nm.
Transmission and scanning electron microscopy performed on
purified MVs showed their spheroid morphology and confirmed
their size [9]. Cytofluorimetric analyses showed the presence of
several adhesion molecules known to be expressed on MSC plasma
membrane such as CD44, CD29, a4- and a5i n t e g r i n sa n dC D 7 3 ,
but not a6-integrin [9]. In addition, MVs did not express HLA-class I
at variance with the cells of origin or HLA-class II. The
morphological analyses performed on MV suspension after staining
with propidium iodide did not show the presence of apoptotic bodies.
We previously characterized the MVs content of mRNA, by
microarray analysis [9], and of microRNA [18].
In selected experiments MVs were treated with 5U RNase
(Ambion Inc., Austin, TX, USA) for 3 h at 37uC; the reaction was
stopped by addition of 10 U/ml RNase inhibitor (Ambion) and
MVs were washed by ultracentrifugation [9]. Treatment with
RNase did not affect MVs morphology and surface protein
expression, evaluated by FACS analyses, as previously reported
[9]. For MVs size and morphology determination, nanoparticle
tracking analysis (NTA) was performed using NanoSight LM10
instrument (NanoSight Ltd., Amesbuty, UK) equipped with the
NTA 2.0 analytic software [27]. The analyses of MVs, treated or
not with RNase, using NanoSight confirmed that RNase-treated
MVs maintained the same physical characteristics of untreated
MVs (Figure 6A).
Total RNA was isolated from MVs, treated or not with RNase,
using the mirVana RNA isolation kit (Ambion) according to the
manufacturer’s protocol. RNA integrity and structure and the
efficacy of RNase treatment were evaluated by Agilent 2100
bioanalyzer (Agilent Technologies Inc., Santa Clara, CA), using the
eukaryotic total RNA 6000 Pico Kit (Agilent Tech.). RNase
treatment reduced 18 and 28S ribosomal RNA residues (Figure 6B).
Quantitative real time-PCR (qRT-PCR) was then performed to
detect mRNA shuttle by MVs, such as ACT B, POLR2E and SUMO-
1 transcripts.The primers used for qRT-PCR areshown inTable 3.
First-strand cDNA was produced from 100 ng of total RNA using
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA). Real-time PCR experiments were
performed in 20 ml reaction mixture containing 5 ng of cDNA
template, the sequence-specific oligonucleotide primers (pur-
chased from MWG-Biotech AG, Ebersberg, Germany, www.
mwg-biotech.com) and the Power SYBRH Green PCR Master
Mix (Applied Biosystems). Negative cDNA controls (no cDNA)
were cycled in parallel with each run. qRT-PCR was performed
using a 48-well StepOne
TM Real Time System (Applied
Biosystems). As shown in figure 6C RNase treatment significantly
reduced the ACT B, POLR2E and SUMO-1 mRNA content in
respect to untreated MVs. Fold change in mRNA expression was
calculated based on cycle threshold (Ct) differences between
treated and untreated MVs, loading the same quantity of RNA
during the reverse transcription procedure.
Murine model of acute kidney injury
Animal studies were conducted in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory
Animals. The protocol was approved by the Committee on the
Bioethics of the University of Torino (Permit Number: 1.3.10).
Models of AKI were performed in male SCID mice (7–8 weeks
old) by subcutaneous injection of a single dose of 12 mg/kg of
Table 2. List and function of genes that significantly differ between cisplatin-treated human tubular cells stimulated or not with
MVs.
TEC CIS +MV versus TEC CIS Official Symbol Functions of encoded protein
Up-regulated BCL2 integral outer mitochondrial membrane protein that blocks the apoptotic death
BCL2L1(BCL-XL) protein belongs to the BCL-2 protein family: the longer isoform acts as an apoptotic inhibitor and the shorter
form acts as an apoptotic activator
BIRC8 a testis-specific inhibitor of apoptosis, but is role is not completed understood
Down-regulated LTA member of the tumor necrosis factor family, is a cytokine produced by lymphocytes; it has been described as
inductor of apoptosis and as negative regulator of fibroblast proliferation
CASP8 member of the cysteine-aspartic acid protease (caspase) family. This protein is involved in the programmed
cell death induced by Fas and various apoptotic stimuli
CASP1 member of the cysteine-aspartic acid protease (caspase) family
BCL2L11 belongs to the BCL-2 protein family and act as an apoptotic activator
TP73 a member of the p53 family of transcription factors involved in cellular responses to stress and development
HRK activator of apoptosis, HRK regulates apoptosis through interaction with death-repressor proteins Bcl2 and
BCL-XL
CARD6 microtubule-associated protein that has been shown to interact with receptor-interacting protein kinases. It
plays pivotal role in signal transduction leading to apoptosis, NF-kB activation and inflammation
doi:10.1371/journal.pone.0033115.t002
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chosen on the basis of preliminary experiments using different
doses of cisplatin (from 10 mg/kg to 20 mg/kg). SCID mice were
kept in our institutional animal facility under well-controlled
conditions of temperature (2262uC), humidity (5565%) and a
12 h/12 h light-dark cycle with access to food and water ad libitum.
Two regimens of MV administration were used (Figure 1):
- single injection of MVs (siMVs): a single dose of 100 mgo f
MVs, or MVs pre-treated with RNase, was injected into the
tail vein eight hours after cisplatin administration;
- multiple injection of MVs (miMVs): a first intravenous (iv)
injection of 100 mg of MVs was performed eight hours after
cisplatin administration followed by iv injection of 50 mgo f
MVs at days 2, 6, 10, 14 and 18 after cisplatin
administration.
Mice (8/group) were killed 4 days after MV administrations,
and kidneys and samples for blood urea nitrogen (BUN) and
creatinine determination were collected.
For survival studies, eight cisplatin treated mice were given with
vehicle alone, eight cisplatin treated mice with siMVs pre-treated
Figure 6. RNase treatment does not modify MV size, but reduces RNA content of MVs. A) Representative MV size analyses by direct
measurement with NTA, showing no difference among MVs treated or not with RNase. B) Representative Bioanalyzer profile, showing the size
distribution of total RNA extracted from MVs treated or not with RNAse. The first peak (left side of each panel) represents an internal standard. The
two peaks in Sample 1 (black arrows) represent 18 S (left) and 28 S (right) ribosomal RNA, only partially detectable in MVs. The red arrows showed the
reduction of 18 and 28 S fragment inside RNAse-treated MVs. C) Histogram showing the expression level of SUMO-1, POLR2 and Act B transcripts in
MVs treated or not with RNase, express as 2
-dCt, as described in material and methods.
doi:10.1371/journal.pone.0033115.g006
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mice with miMVs. The animals were monitored for activity and
physical conditions every day. Mice were followed for up to 21
days after treatments. Each animal was scored using an assessment
form that evaluated each animal’s health as described [28]. The
animal were euthanized through CO2 inhalation.
Renal function
Blood samples for measurement of BUN and plasma creatinine
were collected 4, 14 and 21 days after cisplatin treatment. Serum
creatinine was measured using a colorimetric microplate assay
based on the Jaffe reaction (Quantichrom Creatinine Assay,
BioAssay Systems, Hayward, CA, USA). BUN was measured by
direct quantification of serum urea with a colorimetric assay kit
according to the instruction protocol (Quantichrom Urea Assay,
BioAssay Systems).
Morphological studies
For renal histology 5 mm-thick paraffin kidney sections were
routinely stained with hematoxylin and eosin (Merck, Darmstadt,
Germany). Luminal hyaline casts and cell lose (denudation of
tubular basement membrane) were assessed in non-overlapping
fields (up to 28 for each section) using a 406objective (high power
filed, HPF). Number of casts and tubular profiles showing necrosis
were recorded in a single-blind fashion [4,9].
Apoptosis was measured by terminal transferase-mediated dUTP
nick-end labeling (Tunel) assay (ApopTag Apoptosis Detection Kit;
Millipore Inc., Billerica, MA, USA) according to the manufacturer
protocol. Scoring Tunel-positive cells was carried out by counting
the number of positive nuclei per field in 10 randomly chosen
sections of kidney cortex using 640 magnification.
Immunohistochemistryforthedetectionofproliferationoftubular
cells was performed as previously described [4,9]. Briefly, kidney
sections were subjected to antigen retrieval, and slides were blocked
and labelled with 1:25 dilution of monoclonal anti-BrdU antibody
(Dakocytomation) or 1:400 of monoclonal anti-PCNA (Santa Cruz
Biotechnology, Santa Cruz CA, USA). Immunoperoxidase staining
was performed using 1:300 dilution of anti-mouse HRP (Pierce,
RockfordIL,USA).ScoringforBrdU-andPCNA-positivecellswas
carried out by counting the number of positive nuclei per field in 10
randomlychosensectionsofkidneycortexusing640magnification.
Confocal microscopy analysis was performed on frozen sections
for the detection of specific human proteins POLR2E and
SUMO-1, used as reporters, since their mRNAs are present in
MVs derived from human MSCs, but not in murine tubular
epithelial cells. Section were blocked and labelled with rabbit anti-
human POLR2E (Abcam, Cambridge Science Park, UK)
(1:300 dilution) or rabbit anti-human SUMO-1 (Abcam)
(1:300 dilution). Omission of the primary antibodies or substitu-
tion with non immune rabbit IgG was used as controls. Alexa
Fluor 488 anti-rabbit (Molecular Probes, Leiden, The Nether-
lands) was used as secondary antibody. Confocal microscopy
analysis was performed using a Zeiss LSM 5 Pascal Model
Confocal Microscope (Carl Zeiss International, Germany).
Hoechst 33258 dye (Sigma) was added for nuclear staining.
Apoptosis assays on human tubular epithelial cells
Primary cultures of human TEC were obtained from kidneys
removed by surgical procedures and characterized as previously
described [29,30]. TECs were seeded at 4,000 cells/well into 96-
well plates in DMEM (Sigma) in the presence of different doses of
MVs derived from MSCs or from fibroblasts (10 or 30 mg/ml).
Apoptosis was evaluated using the Tunel assay (ApopTag
Apoptosis Detection Kit) 48 hours after the beginning of the
experiments, as previously described [9]. We used, as apoptotic
stimuli, serum deprivation, or stimulation with 5 mg/ml of
cisplatinum in DMEM plus 3% fetal calf serum (FCS).
Immunofluorescence for human protein expression on
TECs
Indirect immunofluorescence was performed on TECs cultured
on chamber slides (Nalgen Nunc International, Rochester, NY,
USA) and stimulated for 1 day in the presence of 5 mg/ml of
cisplatin (Sigma) and 50 mg of different preparations of MVs. The
Table 3. Primers used in qRT-PCR experiments.
Name Official symbol Sequences
Polymerase (RNA) II (DNA directed) POLR2E Forward 5’-GCTCTGGAAAATCCGCAAGA-3’
Reverse 5’-TCCTCCAGGGTCTGGTCAAG-3’
Senp2 SUMO-1 Forward 5’-AAATAAGATCGACCAATGCAAGTG-3’
Reverse 5’-TCACAGTCCAGGAGTGAAGTAATCA-3’
Actin B ACT B Forward 5’-TGA AGATCAAGATCATTGCTCCTC-3’
Reverse 5’-CACATCTGCTGGAAGGTGGAC-3’
Caspase 1 CASP1 Forward 59-CCGCAAGGTTCGATTTTCAT-3’
Reverse 59-TTTTAATGTCCTGGGAAGAGGTAGA-3’
Lymphotoxin alpha (TNF superfamily, member 1) LTA Forward 59-CACCTCATTGGAGACCCCAG-3’
Reverse 59-TGGGAGTAGACGAAGTAGATGCC-3’
Caspase 8 CASP8 Forward 5’-TGATGACATGAACCTGCTGGAT-3’
Reverse 5’-TGTCATTACCCCACACAACTCCT-3’
Baculoviral IAP repeat-containing 8 BIRC8 Forward 59-ACCTGACCATTGAGGACCTGG-3’
Reverse 59-TGTAGTCGTGGCCCTGCTTC-3’
B-cell CLL/lymphoma 2 Bcl2 Forward 59-GGAGGCTGGGATGCCTTT-3’
Reverse 59-GCCAAACTGAGCAGAGTCTTCA-3’
BCL2-like 1 BCL2L1(BCL-XL) longer isoform Forward 59-GGCTGGGATACTTTTGTGGAAC-3’
Reverse 59-ACAGTCATGCCCGTCAGGA-3’
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Forward 59-TGGAAGGACTCATGACCACAGT-3‘
Reverse 59- CATCACGCCACAGTTTCCC-3‘
doi:10.1371/journal.pone.0033115.t003
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and permeabilized with Hepes-Triton 6100 buffer (Sigma). The
following antibodies were used: rabbit anti-human POLR2E
(Abcam) and rabbit anti human SUMO-1 (Abcam). Omission of
the primary antibodies and substitution with non immune rabbit
IgG were used as controls. Alexa Fluor 488 anti-rabbit (Molecular
Probes) was used as secondary antibody. Hoechst 33258 dye
(Sigma) was added for nuclear staining.
Reverse transcriptase PCR (RT-PCR).
Total RNA extracted from TECs, after incubation with 5 mg/
ml of cisplatin and 250 mg of MVs for 1 hour, was submitted to
RT-PCR [9] using the primer for human POLR2E reported in
table 1. Bands of the expected size (90 pb) were detected in a 4%
Agarose gel after electrophoresis. cDNA from a preparation of
human bone marrow MSC was used as positive control.
Apoptosis RT2 profile PCR arrays on tubular epithelial
cells
TECs were seeded into T75 flasks at 80% of confluence and
treated with 5 mg/ml of cisplatin (Sigma) in the presence or
absence of MVs (30 mg/ml) in DMEM plus 3% FCS for 24 hours.
Untreated tubular cells were used as control. Total RNA was then
isolated from different cell preparations using the mirVana RNA
isolation kit (Ambion) and cDNA was synthesized from 1 mgo f
RNA imput. The expression of 84 apoptosis- related genes was
examined using the RT2 Profiler PCR array (SABioscience,
Qiagen, Valencia, CA, USA) according to the manufacturer
instructions using the Applied Biosystems 7900HT real-time PCR
instrument. Data analysis was performed using the online
SABioscience software and the expression levels of the mRNA of
each gene in cisplatin and cisplatin plus MVs treated cells were
normalized using the expression of GAPDH, ACT B, B2M and
RPL13A as housekeeping genes and then compared with the data
obtained from untreated cells. The results were confirmed by
qRT-PCR performed using individual RNA samples from each
group of cells by a 48-well StepOne
TM Real Time System (Applied
Biosystems) [31]. The primers used for qRT-PCR are shown in
Table 3.
Statistical analysis
Resultsaregenerallyexpressedasmean6standarddeviation(SD).
Statistical analysis was performed by using the Student t-tests
(unpaired, 2-tailed), ANOVA with Newmann-Keuls’ or ANOVA
with Dunnet’s multicomparison tests as appropriate. A p value
of,0.05was considered significant.
For survival experiments, a log-rank test was conducted, and
p,0.05 was deemed significant.
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